Report Detail
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, Status and Forecast 2019-2025
- RnM3798983 |
- 02 October, 2019 |
- Global |
- 99 Pages |
- QYResearch |
- Pharma & Healthcare
Kidney cancer/ renal cell carcinoma (RCC) is among ten most commonly observed cancer these days. It is sixth common cancer observed in men and it is the tenth most common cause of cancer for women.
In 2018, the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
Active Biotech Ab
Amgen
Bayer AG
Cipla Limited
Roche Holding AG
Glaxosmithkline Plc
Novartis Ag
Pfizer, Inc.
Market segment by Type, the product can be split into
Afinitor (Everolimus)
Avastin (Bevacizumab)
Cabomety (Cabozantinib)
Inlyta (Axitinib)
Nexavar (Sorafenib)
Proleukin (Aldesleukin)
Torisel (Temsirolimus)
Sutent (Sunitinib)
Votrient (Pazopanib)
Market segment by Application, split into
Hospitals
Clinic
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs status, future forecast, growth opportunity, key market and key players.
To present the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered
- 1.4 Market Analysis by Type
- 1.4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Type (2014-2025)
- 1.4.2 Afinitor (Everolimus)
- 1.4.3 Avastin (Bevacizumab)
- 1.4.4 Cabomety (Cabozantinib)
- 1.4.5 Inlyta (Axitinib)
- 1.4.6 Nexavar (Sorafenib)
- 1.4.7 Proleukin (Aldesleukin)
- 1.4.8 Torisel (Temsirolimus)
- 1.4.9 Sutent (Sunitinib)
- 1.4.10 Votrient (Pazopanib)
- 1.5 Market by Application
- 1.5.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application (2019-2025)
- 1.5.2 Hospitals
- 1.5.3 Clinic
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Global Growth Trends
- 2.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size
- 2.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Growth Trends by Regions
- 2.2.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Regions (2019-2025)
- 2.2.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Regions (2014-2019)
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Challenges
- 2.3.4 Porter’s Five Forces Analysis
3 Market Share by Key Players
- 3.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by by Players
- 3.1.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by by Players (2014-2019)
- 3.1.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by by Players (2014-2019)
- 3.1.3 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players Head office and Area Served
- 3.3 Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product/Solution/Service
- 3.4 Date of Enter into Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
- 4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2014-2019)
- 4.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2014-2019)
5 North America
- 5.1 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2014-2019)
- 5.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in North America
- 5.3 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type
- 5.4 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application
6 Europe
- 6.1 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2014-2019)
- 6.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in Europe
- 6.3 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type
- 6.4 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application
7 China
- 7.1 China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2014-2019)
- 7.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in China
- 7.3 China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type
- 7.4 China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application
8 Japan
- 8.1 Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2014-2019)
- 8.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in Japan
- 8.3 Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type
- 8.4 Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application
9 Southeast Asia
- 9.1 Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2014-2019)
- 9.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in Southeast Asia
- 9.3 Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type
- 9.4 Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application
10 India
- 10.1 India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2014-2019)
- 10.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in India
- 10.3 India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type
- 10.4 India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application
11 Central & South America
- 11.1 Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2014-2019)
- 11.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players in Central & South America
- 11.3 Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type
- 11.4 Central & South America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application
12 International Players Profiles
- 12.1 Active Biotech Ab
- 12.1.1 Active Biotech Ab Company Details
- 12.1.2 Company Description and Business Overview
- 12.1.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
- 12.1.4 Active Biotech Ab Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2014-2019))
- 12.1.5 Active Biotech Ab Recent Development
- 12.2 Amgen
- 12.2.1 Amgen Company Details
- 12.2.2 Company Description and Business Overview
- 12.2.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
- 12.2.4 Amgen Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2014-2019)
- 12.2.5 Amgen Recent Development
- 12.3 Bayer AG
- 12.3.1 Bayer AG Company Details
- 12.3.2 Company Description and Business Overview
- 12.3.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
- 12.3.4 Bayer AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2014-2019)
- 12.3.5 Bayer AG Recent Development
- 12.4 Cipla Limited
- 12.4.1 Cipla Limited Company Details
- 12.4.2 Company Description and Business Overview
- 12.4.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
- 12.4.4 Cipla Limited Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2014-2019)
- 12.4.5 Cipla Limited Recent Development
- 12.5 Roche Holding AG
- 12.5.1 Roche Holding AG Company Details
- 12.5.2 Company Description and Business Overview
- 12.5.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
- 12.5.4 Roche Holding AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2014-2019)
- 12.5.5 Roche Holding AG Recent Development
- 12.6 Glaxosmithkline Plc
- 12.6.1 Glaxosmithkline Plc Company Details
- 12.6.2 Company Description and Business Overview
- 12.6.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
- 12.6.4 Glaxosmithkline Plc Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2014-2019)
- 12.6.5 Glaxosmithkline Plc Recent Development
- 12.7 Novartis Ag
- 12.7.1 Novartis Ag Company Details
- 12.7.2 Company Description and Business Overview
- 12.7.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
- 12.7.4 Novartis Ag Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2014-2019)
- 12.7.5 Novartis Ag Recent Development
- 12.8 Pfizer, Inc.
- 12.8.1 Pfizer, Inc. Company Details
- 12.8.2 Company Description and Business Overview
- 12.8.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
- 12.8.4 Pfizer, Inc. Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2014-2019)
- 12.8.5 Pfizer, Inc. Recent Development
13 Market Forecast 2019-2025
- 13.1 Market Size Forecast by Product (2019-2025)
- 13.2 Market Size Forecast by Application (2019-2025)
- 13.3 Market Size Forecast by Regions
- 13.4 North America
- 13.5 Europe
- 13.6 China
- 13.7 Japan
- 13.8 Southeast Asia
- 13.9 India
- 13.10 Central & South America
14 Analyst's Viewpoints/Conclusions
15 Appendix
- 15.1 Research Methodology
- 15.1.1 Methodology/Research Approach
- 15.1.1.1 Research Programs/Design
- 15.1.1.2 Market Size Estimation
- 15.1.1.3 Market Breakdown and Data Triangulation
- 15.1.2 Data Source
- 15.1.2.1 Secondary Sources
- 15.1.2.2 Primary Sources
- 15.1.1 Methodology/Research Approach
- 15.2 Disclaimer
Summary:
Get latest Market Research Reports on Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs. Industry analysis & Market Report on Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs is a syndicated market report, published as Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
